Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXBRCI)

Drug Name

NSC-180246 Drug Info

Synonyms

Poriol; NSC180246; 14348-16-4; NSC-180246; MLS000876957; SMR000440646; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-6-methyl-2,3-dihydro-4H-chromen-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methyl-chroman-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methyl-2,3-dihydrochromen-4-one; 6-methylnaringenin; NSC 180246; AC1L6Z6F; CHEMBL484640; cid_301798; MEGxp0_000360; ACon1_000765; BDBM50571; MolPort-001-740-534; HMS2269A20; LMPK12140301; 4',5,7-Trihydroxy-6-methylflavanone; NCGC00169381-01; BRD-A47074844-001-01-5

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 301798
CAS Number: CAS 14348-16-4
TTD Drug ID: DMXBRCI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Approved Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[3]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[3]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[4]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[5]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[6]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[7]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[8]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[8]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[9]
Ziconotide	DMSLJP4	Pain	MG30-MG3Z	Approved	[10]
Hesperidin	DMI5DW1	Vascular purpura	3B60	Approved	[1]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[11]
Ralfinamide	DMUNMY0	Neuropathic pain	8E43.0	Phase 3	[12]
CNV-2197944	DMLT7JV	Pain	MG30-MG3Z	Phase 2	[13]
Ritanserin	DM0X36Y	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[14]
CNSB-004	DMHAI0M	Pain	MG30-MG3Z	Preclinical	[15]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[16]
PD-157667	DM61NFD	N. A.	N. A.	Terminated	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[1]
Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)	TT4FDG6	CAC1B_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
2	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Prelude Therapeutics.
5	Clinical pipeline report, company report or official report of AbbVie.
6	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
7	Clinical pipeline report, company report or official report of Amgen.
8	Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
9	Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
10	Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
11	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
12	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
13	Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
14	N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12.
15	CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73.
16	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
17	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.